The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc's newly approved Alzheimer's disease drug is slightly above expectations, but should not dent demand for the promising therapy, Wall Street analysts said.
newly approved Alzheimer's disease drug is slightly above expectations, but should not dent demand for the promising therapy, Wall Street analysts said.to the drug, Leqembi, and the decision was hailed by patient groups."As a result of this higher than expected pricing, we think it is reasonable to see peak sales reach $15.2 billion worldwide," BMO analyst Evan Seigerman said in a research note.
However, the price tag is lower than that of Eisai and Biogen's first Alzheimer's disease drug, Aduhelm, which was initially priced at $56,000 annually before the drugmakers halved the price amid controversy over its approval. "We think this level of pricing is unlikely to generate the intense scrutiny that followed the initial $56K Aduhelm price tag," said Baird analyst Brian Skorney in a research note.
"We don't expect this price to stunt demand for a product that, in the best case scenario, could slow clinical decline by multiple years."including reimbursement restrictions by Medicare, the U.S. government insurance program for Americans aged 65 and older who represent some 90% of individuals likely to be eligible for Leqembi.
Eisai and Biogen said on Saturday the Japanese drugmaker had applied for full approval by the U.S. Food and Drug Administration. Some analysts expect broader coverage by Medicare if the drug is granted full approval.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
New Alzheimer's drug: What to know as Leqembi hits the marketHere are some things to know about the FDA's approval of lecanemab, to be sold under the brand name Leqembi.
Weiterlesen »
New Alzheimer's drug: What to know as Leqembi hits the marketHere are some things to know about the FDA's approval of lecanemab, to be sold under the brand name Leqembi.
Weiterlesen »
EXPLAINER: New drug slows Alzheimer's but comes with caveatsWASHINGTON (AP) — A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease. It's a long-needed new treatment, but experts also are voicing a lot of caution: The drug isn't a cure, it's only intended for early-stage patients, requires IV doses every two weeks, and comes with some safety concerns.
Weiterlesen »
U.S. FDA approves Alzheimer's drug that appears to slow rate of cognitive declineThe drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain.
Weiterlesen »
EXPLAINER: New drug slows Alzheimer's but comes with caveatsIt's a long-needed new treatment, but experts also are voicing a lot of caution: The drug isn't a cure, it's only intended for early-stage patients, requires IV doses every two weeks, and comes with some safety concerns.
Weiterlesen »
New Alzheimer's Drug Slows Progression of Disease But It Comes With CaveatsA new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease.
Weiterlesen »